EGFR and non-small cell lung carcinoma: To assess our ability to detect subclonal mutations, we examined EGFR T790M in the non-small cell lung carcinoma subset of our dataset, where the mutation would be expected to occur in tyrosine kinase inhibitor resistant subclones.